Essential medicines are still essential

According to the Expert Committee, "Inclusion on the EML of all DAAs proposed in the applications aims at promoting competition among available alternatives and allowing for the selection of optimal combination treatment regimens, which may or may not be existing fixed-dose combinations"....

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2015-10, Vol.386 (10004), p.1601-1603
Main Authors: Gray, Andy L, Wirtz, Veronika J, t Hoen, Ellen F M, Reich, Michael R, Hogerzeil, Hans V
Format: Article
Language:English
Subjects:
Drug resistance
Internal Medicine
Pharmaceutical industry
Pharmaceutical Preparations - classification
Pharmaceutical Preparations - economics
Pharmaceuticals
Property rights
Public health
Regulatory approval
Trade agreements
World Health Organization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the Expert Committee, "Inclusion on the EML of all DAAs proposed in the applications aims at promoting competition among available alternatives and allowing for the selection of optimal combination treatment regimens, which may or may not be existing fixed-dose combinations". Key generic-producing countries have implemented the 1995 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), and now have to provide 20-year patent terms for pharmaceutical products.13 Some recent bilateral and regional trade agreements even add further barriers to generic competition.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(15)00514-0